Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon M Blumenthal

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisJulia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2018
Clinical Development of Novel Drug-Radiotherapy CombinationsSaif S Ahmad, Marka R Crittenden, Phuoc T Tran, et al.
Oncotarget|October 21, 2014
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumorsGideon M Blumenthal, Joell J Gills, Marc S Ballas, et al.
The Lancet. Oncology|December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.
Translational Lung Cancer Research|August 2, 2019
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancerTakefumi Komiya, Regan M Memmott, Gideon M Blumenthal, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 3, 2017
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall responseHongshan Li, Jingyu Yu, Chao Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2015
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerSean Khozin, Gideon M Blumenthal, Lijun Zhang, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisJulia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.
Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2018
Clinical Development of Novel Drug-Radiotherapy CombinationsSaif S Ahmad, Marka R Crittenden, Phuoc T Tran, et al.
Oncotarget|October 21, 2014
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumorsGideon M Blumenthal, Joell J Gills, Marc S Ballas, et al.
The Lancet. Oncology|December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.
Translational Lung Cancer Research|August 2, 2019
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancerTakefumi Komiya, Regan M Memmott, Gideon M Blumenthal, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 3, 2017
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall responseHongshan Li, Jingyu Yu, Chao Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2015
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerSean Khozin, Gideon M Blumenthal, Lijun Zhang, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Pageof 9